MGC Pharmaceuticals Limited
MGCLF · OTC
12/30/2023 | 6/30/2023 | 12/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.39 | 0.03 | 0.07 | -0.02 |
| FCF Yield | -0.72% | -28.40% | -12.32% | -13.19% |
| EV / EBITDA | -185.81 | -2.92 | -6.07 | -7.44 |
| Quality | ||||
| ROIC | -45.68% | -116.48% | -55.22% | -57.21% |
| Gross Margin | -97.08% | -22.35% | 40.29% | 51.39% |
| Cash Conversion Ratio | 1.12 | 0.53 | 0.62 | 0.52 |
| Growth | ||||
| Revenue 3-Year CAGR | 31.58% | 104.24% | 150.89% | 164.24% |
| Free Cash Flow Growth | -52.79% | 25.81% | 1.37% | 8.74% |
| Safety | ||||
| Net Debt / EBITDA | -0.53 | -1.00 | -0.82 | -0.33 |
| Interest Coverage | -13.99 | -45.84 | -60.57 | -78.96 |
| Efficiency | ||||
| Inventory Turnover | 0.96 | 0.65 | 0.94 | 0.57 |
| Cash Conversion Cycle | -14.99 | -17.60 | -30.66 | 21.87 |